Overcoming antigen escape with CAR T-cell therapy
HJ Jackson, RJ Brentjens - Cancer discovery, 2015 - AACR
HJ Jackson, RJ Brentjens
Cancer discovery, 2015•AACRSotillo and colleagues describe the molecular events associated with apparent loss of target
antigen expression following CAR T-cell therapy. We propose that broader immune
activation is required to prevent outgrowth of tumor antigen escape variants following
targeted therapies. Cancer Discov; 5 (12); 1238–40.© 2015 AACR. See related article by
Sotillo et al., p. 1282.
antigen expression following CAR T-cell therapy. We propose that broader immune
activation is required to prevent outgrowth of tumor antigen escape variants following
targeted therapies. Cancer Discov; 5 (12); 1238–40.© 2015 AACR. See related article by
Sotillo et al., p. 1282.
Abstract
Summary: Sotillo and colleagues describe the molecular events associated with apparent loss of target antigen expression following CAR T-cell therapy. We propose that broader immune activation is required to prevent outgrowth of tumor antigen escape variants following targeted therapies. Cancer Discov; 5(12); 1238–40. ©2015 AACR.
See related article by Sotillo et al., p. 1282.
AACR